11 - Bibliografia - 1ª Parte


Equipe Editorial Bibliomed

O asterisco (*) designa um artigo que foi de especial valor para preparação deste número de Population Reports.

1. ABDEL-SAYED, W.S., TOPPOZADA, H.K., SAID, S.A., and EL-SAYED, O.K. Some metabolic and hormonal changes in women using long acting injectable contraceptives. Alexandria Journal of Pharmaceutical Sciences 3(1):29-32. Mar. 1989.

2 . ABEYWICKREMA, D. (Family Planning Association of Sri Lanka) [Logistics and infection prevention] Personal communication, DK. 29, 1993.

3. AD HOC CONSULTATIVE PANEL ON DEPOT ME MEDROXYPROGESTERONE ACETATE. Report to USAID of the Ad Hoc Consultative Panel on Depot Medroxyprogesterone Acetate, Newyork City, Dec. 7-8,1978. M. 1980. 59 p. (Unpublished)

4 . AHMAD, S., ISLAM, M.N., and RAHMAN, S. Determinants of acceptance of injectable contraception in Bangladesh. Dhaka, Bangladesh, Associates for Research Training and Computer Processing Ltd. and the National Institute of Population Research and Training, Nov. 1992. 156 p.

5. AKBAR, J., CHAKRABORTY, I., JAHAN, N., PHILLIPS, J.F., and SATTERWAITE, A. P. Dynamics of depot medroxyprogesterone acetate (DMPA) use effectiveness, in the Matlab Family Planning Health Services Project. Presented at the 7th Annual Contributors Conference of Bangladesh Fertility Research Programme, Dhaka, DK. 8-9, 1982.19p.

6. AMATAYAKUL, K. The effects of Depo-Provera on carbohydrate, lipids and vitamin metabolism. Journal of Steroid Biochemistry 11(1B): 475-481. Jul. 1979.

7. AMATAYAKUL, K., SIVASSOMBOON, B., and SINGKAMANI, R. Effects of medroxyprogesterona, acetate on serum lipids, protein, glucose tolerance and liver function in Thai women. Contraception 21(3): 283-297. Mar. 1980.

8. AMATAYAKUL, K., SIVASOMBOON, B., and THANANGKUL, O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 22(6):605-622. DK. 1980.

9. ANONYMOUS. Counseling about side effects improves contraceptive continuation Network 12(2): 3. Sep. 1991.

10. ANONYMOUS. UK: Beagle carcinogenicity studies no, longer required for Progestogens. Scrip World Pharmaceutical News, Nº. 430, Oct. 17,1979. p. 3.

11. APELO, DIE LA CRUZ, J.R, and CANCIO-LOPEZ F. Acceptability of injectable contraception in the Philippines. IPPF Medical Bulletin 8(2):1-2. Apr. 1974.

12. ARIWONGSE, B.C. An overview of the FPNP injectable programme. In: Palan, VT. and Nawi, M., eds. Recent advances in contraceptive technology: Proceedings of the seminar held 14-20 Oct. 1987 in Chiang Mai, Thailand, International Planned Parenthood Federation, East & Southeast Asia and Oceania Region. 1987. p. 94-96.

13. ASHMAN, J.A.M. Monthly injectable contraceptives and breast cancer. Thesis for Master of Science degree, University of Washington, [Seattle, Washington], 1990. 77 p.

14. ASSOCIATION OF REPRODUCTIVE HEALTH PROFESSIONALS (ARHP). and UNIVERSITY OF FLORIDA (UF). Family planning update: Injectable Contraceptives, [Video] Washington, D.C. and Jacksonville, Florida, ARHP. and UF, Sep. 3,1992.

15.AYDINLIK,S.(Schering) [Teratogenic effects of NET-EN] Persornal commutnication to H.L. Ellis, Ellis Pharmaceutical Consulting, May 31,1994.

16. AYLWARD, B., KANE, M., MCNAIR-SCOTT, R., and HU, D.J. Risk of human immunodeficiency virus and Hepatitis-B vim transmission through unsafe injections: Model- based estimates. [Draft] 1994.22p.

17. BABCOCK, J.C., GUTSELL, E.S., HERR, M.E., HOGG, I.A., STUCKI, J.C., BARNES, L.E., and DULIN, W.E. 6-Methyl-17-Hydroxyprogesterone 17-acylates: A new class of potent progestins. Journal of the American Chemical Society 80(pt. 2):2904-2905. Apr.-Jun. 1958.

18. BACHMAN, G. (SOMARC) [injectables in social marketing programs] Personal communication, Apr. 28,1995.

19. BAKOUAN, D., SEBGO, P., ASKEW, L, OUÉDRAOGO, Y., TAPSOBA, P., VIADRO, C., and KANON, S. Analyse, situationnelle du programme da planification familiale au Burkina Faso. [Situation analysis of the family planning program in Burkina Faso][FRE] [Ougadougou], Burkina Faso, Burkina Faso. Department of Health, Feb. 1992. 69 p.

20. BALDWIN, G.B. The McCormick Family Planning Program in Chiang Mai, Thailand. Studies in Family Planning 9(12): 300-312. Dec. 1978.

21. BANERJEE, S.K., BAVEJA, R., BHATT, R-V, et al. Return of fertility following discontinuation of an injectable contraceptive-Norethisterone oenanthate (NET EN) 200mg dose. Contraception 34(6): 573-582. DK. 1986.

22. BANGLADESH. MINISTRY OF HEALTH. NATIONAL INSTITUTE FOR POPULATION RESEARCH AND TRAINING IMPORT). and MITRA AND ASSOCIATES (MA). and DEMOGRAPHIC AND HEALTH SURVEYS (DHS). MACRO INTERNATIONAL. Bangladesh Demographic and Health Survey 1993-94: PW liminary report. Dhaka, Bangladesh. arid Calverton, Maryland, NIPORT. and MA. and DHS, Jul. 1994. 37 p.

23. BASNAYAKE, S. (Family Manning Association of Sri Lanka) [Injectables in Sri Lanka] Personal communication, Apr. 19,1995.

24.BASNAYAKE,S. A study of 157 women who conceived after discontinuation of Depo Provera. [Colombo, Sri Lanka, Family Planning Association of Sri Lanka], Oct. 1981. 9 p.

25. BASNAYAKE, S. A Study of Depo-Provera users in a family planning clinic in Sri Lanka. Presented at the Family Planning Association of Sri Lanka 25th Anniversary Scientific Congress, [Colombo, Sri lanka], Mar. 26-28.13 p.

26. BASSOL, S. and GARZA-FLORES, I. Review of ovulation return upon discotinuation of once-a-month injectable contraceptives. Contraception 49(5): 441-453. May 1994.

27. BASSOL, 5., HERNANDEZ, C., NAVA, M.P., TRUJILLO, A.M., and LUZ DE LA CRUZ, D. A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives. Contraception 51(5):307-311. may 1995.

28. BECTON DICKINSON AND COMPANY (B-D). SoloShot syringe. [Foldout brochure] Franklin Lakes, New Jersey, B-D, 1991. 6 P.

29. BELSEY, E.M., D'ARCANGUES, C., CARLSON, N., and WORLD HEALTH ORGANIZATION. TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION. Determinants of menstrual bleeding patterns among women using natural and hormonal methods of contraception: 2. The influence of individual characteristics. Contraception 38(2): 243-257. Aug. 1988.

30. BELSEY, E.M. and FARLEY, T.M.M. The analysis of menstrual bleeding patterns: A review. Contraception 38(2):129-156. Aug. 1988.

31. BELSEY, E.M., MACHIN, D., and D'ARCANGUES, C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception, 34(3): 253-260. Sep. 1986.

32 . BELSEY, E.M., PEREGOUDOV, S., and TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION, SPECIAL PROGRAMME OF RESEARCH, DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Determinants of menstrual bleeding patterns among women using natural and hormonal methods of contraception: 1. Regional variations. Contraception 38: 227-242.1988.

33. BELSEY, E.M. and WORLD HEALTH ORGANIZATION. TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception 38(2): 207-225. Aug. 1988.

34. BENNETT, K. (Upjohn) (Side effects and registration of DMPA) Personal communication, DK. 19,1994 and Feb. 21,1995.

35. BENNETT, R.C. Depo medroxyprogesterone acetate (Depo Provera) for contraception. Jun. 19, 1992. 15 P. (Unpublished)

36 , BENSON, R.C. and PERNOLL, M.L. Benson and Pernolls handbook of obstetrics and gynecology. 9th ed. New York, McGraw-Hill, 1994. 817 p.

37. BINZEN, S. Improving contraceptive supply management. Family Planning manager 1(4):1-20, Sep.-Oct. 1992.

38. BISGROVE, E. (Family Health International) [DMPA and bone density] Personal communication, Jun. 28,1995.

39. BLOCH, B. Depot medroxyprogesterone acetate (Depo-Provera) as a contraceptive preparation. South African medical journal 45(28):777-780. Jul. 17, 1971.

40. BRACKEN, M.B. Oral contraception and congenital malformations in offspring A review and meta-analysis of the prospective studies. obstetrics and Gynaecology 76(3, Pt.2): 552-557. Sep. 1990.

41. BRAT, T.M. Acceptability of Depo-Provera as a reliable contraceptive method. [Abstract] In: Kleinman, R. and Pickles, VR. eds. In: Kleinman, R. and Pickles, VR., eds. 7th World Congress, Fertility and Sterility, Oct. 1971. Amsterdam, Excerpta Medica Foundation, 1971. (International Congress Series Nº 234a) p. 85.

42. FRIEND, A., FAUVEAU, V, and CHAKRABORTY, 1. Contraceptive use and breast- Feeding duration in rural Bangladesh. European Journal of Clinical Nutrition 45(7): 341-346. Jul. 1991.

43. BROOKS, G.G. Anaphylactoid shock with medroxyprogesterone acetate: A use report. journal of the Louisiana State medical Society 126(11): 397-399. Nov. 1974.

44. BRUZZI, P., NEGRI, E., LA VECCHIA, C., DECARLI, A., PALLI, D., PARAZZINI, F., and ROSSELLI DEL TURCO, M. Short term increase in risk of breast cancer after full term pregnancy. British Medical Journal 297(6656):1096-1098. Oct. 29,1988.

45. CAILLOUX, L. (John Snow) [DMPA shipments by USAID] Personal communication, Feb. 28,1995.

46. CALDWELL, I.C. and CALDWELL, P. What does the Matlab fertility experience really show? [Canberra, Australia], Australian National University. National Centre for Epidemiology and Population Health, 1992. (Health Transition Working Paper Nº. 14) 27 p.

47. CHAUDHURI, C., BHOWMIK, T., and MUKHERJEA, M. Alterations in blood sugar, protein, and lipid levels in Indian women by norethisterone enanthate. International Journal of Fertility 32(3): 240-244. May-Jun. 1987.

48. CHEVANNES, B. and MCDONALD, O. (Jamaican National Family Planning Board) [Injectables in Jamaica] Personal communication, DK. 22,1993.

49. CHEZ, R.A. Proceedings of the symposium Progesterone, progestins, and fetal development. Fertility and Sterility 30(1):16-26. Jul. 1978.

50. CHINVANTHANANOND, P. and SAMRANSAMRUAJKIT, S. New regimen of injectable contraceptives. Journal of the Medical Association of Thailand 70(4): 198-203. Apr. 1987.

51. COLEMAN, P. (Population Communication Services) [DMPA in the Philippines) Personal communication, Mar. 14,1994.

52. COSTA, T.H.M. and DOREA, I.G. Concentration of fat, protein, lactose and energy in milk of mothers using hormonal contraceptives. Annals of Tropical Paediatrics 12(2): 203-209.1992.

53. COUPLES CHOICE. Facts about Depo-Provera. Manila Bulletin, May 1, 1994.

54. CROMER, B.A., SMITH, R.D., BLAIR, J.M., DWYER, J., and BROWN, R.T. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception. Pediatrics 94(5): 687-694. Nov. 1994.

55. CROWLEY, J. (USAID) [Shelf life of DMPA] Personal communication, DK. 22,1994.

56. CROXATTO, H.B. and DIAZ, S. Post-partum contraception. In: Diczfalusy, E. and Bygdeman, M., eds. Fertility regulation today and tomorrow, New York, Raven, 1987. (Serono Symposia Publications Vol., 36) p. 181-195.

57. CUNDY, T., CORNISH, I., EVANS, M.C., ROBERTS, H., and REID, IX Recovery of bone density in women who stop using medroxyprogesterone acetate. British Medical Journal 308(6923): 247-248. Jan. 22, 1994.

58. CUNDY, T., EVANS, M., ROBERTS, H., WATTIE, D., AMES, R., and REID, I.R. Bone density in women receiving depot medroxytrogesterone acetate for contraception. British Medical Journal 303(6793):13-16.Jul. 6,1991.

59. CZEIZEL, A.E. and KODAJ, I. A changing pattern in the association of oral contraceptives and the different groups of congenital limb deficiencies. Contraception 51(1): 19-24. Jan. 1995.

60. D'ARCANGUES, C. (WHO) [injectable research] Personal communication, Mar. 31,1994.

61. DAHLBERG, K. Some effects of depo-medroxyprogesterone acetate (DMPA): Observations in the nursing infant and in the long-term user. International Journal of Gynaecology and Obstetrics 20(1):43-48. Feb. 1982.

62. DAS GUPTA, A. (JHSPH/PCS/BangIadesh) (Injectable contraception interviews) Personal communication, [1994].

63. DATEY, 5., GAUR, L.N., and SAXENA, B.N. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, ml pills)An Indian experience. Contraception 51(3):155-165. Mar, 1995.

64. DAMS, M.E. and WIED, G.L. Long-acting progestational agents. Geburtshille und Frauenheilkunde 17(10): 916-928. 1957.

65. DE CEULAER, K, GRUBER, C., HAYES, R., and SERJEANT, G.R. Medroxyprogesteronee acetate and homozygous sickle-cell disease. Lancet 2(8292): 229-231. Jul. 31,1982.

66. DIAZ, J. and DIAZ, M. Quality of care in family planning in Latin America. Advances in Contraception 9(2):117-128.1993.

67. DISAIA, P.J. Ovarian neoplasms. In: Scott, I.R., Disaia, P.J., Hammond, C.S., and Spellacy, W.N., eds. Danforth's Obstetrics and gynecology. 7th ed. Philadelphia, J.B. Lippincott, 1994. P. 969-1018.

68. DKT INTERNATIONAL (DKT). 1993 contraceptive social marketing statistics. Washington, D.C., DKT, Jul. 1994.6 p.

69. DONEGAN, W.L. Diseases of the breast. In: Danforth, D.N. and Scott, J.R., eds. obstetrics and gynecology 5th ed. Philadelphia, J.B. Lippincott, 1986. p. 1156-1175.

70. DUNCAN, G.W. and KIRTON, K.T. Depo-Provera: Pharmacology and toxicology. In: Zambrano, D., ed. Depo-provera (medroxyprogesterone acetate) for contraception: A current perspective of scientific, clinical and social issues. Proceedings of an international symposium held on 19-20 Nov. 1992. Oxford, England, Oxford Clinical Communications, 1992. p. 7- 25.

71. EL ARIFEEN, S. and MOOKHERJI, S. The urban MCH-FP initiative: A partnership for urban health and family planning in Bangladesh. An asessment of programme needs in zone 3 of Dhaka City. [Dhaka], Concerned Women for Family Planning. and Bangladesh. Ministry of Health and Family Welfare. and Centre for Health and Population Research, 1995. 59 P.

72. EL-MAHGOUB, S., KARIM, M., and AMMAR, R. Long-term use of depot medroxy progesterone acetate as a contraceptive. Acta Obstetricia et Gynecologica Scandinavia 51: 251- 255.1972.

73. EL-ZANATY, F.H., SAYED, H.A.A., ZAKY, H.H.M., and WAY, A.A. Egypt Demographic and Health Survey 1992. Cairo and Calverton, Maryland, National Population Council. and Macro International, Nov. 1993. 317 p.

74. ELLIS, H. (Ellis Consulting) [Norethistermie-Enanthate and Mesigyna] Personal communication, Nov. 3,1993.

75. ENK, L., LANDGREN, B.-M., LINDBERG, U.-B., SILFVERSTOLPE, G., and CRONA, N. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Hormone and Metabolic Research 24(2): 85-89. Feb. 1992.

76. FAHMY, K., ABDEL-RAZIK, M., SHAARAWAY, M., AL-KHOLY, G., SAAD, S., WAGDI, A., and AL-AZZONY, M. Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception 44(4):419- 430. Oct. 1991.

77. FAHMY, K,, KHAIRY, M., ALLAM, G., GOBRAN, F., and ALLOUSH, M. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 44(4): 431-444. Oct. 1991.

78. FAJUMI, I.D. Alterations in blood lipids and side effects induced by Depo-Provera in Nigerian women. Contraception 27(2):161-175. Feb. 1983. 79. FAJUMI, J.O. The effects of depo-provera on serum protein levels in Nigerian women. Journal of Steroid Biochemistry 20(2): 581-583. Feb. 1984.

90. FALASE, E.A.O., OTOLORIN, E.D., and LADIPO, O.A. Experience with the use of depo-medroxyprogesterone acetate in a Nigerian population. African journal of medicine and Medical Sciences 17(4): 209-213. DK. 1988.

81. FAMILY HEALTH INTERNATIONAL (FHI). Injectables, [Loose leaf binder] Research Triangle Park, North Carolina, FHI, 1993. (Contraceptive Technology Update Series)

82. FERRAZ, E.H., FERREIRA, J.Q., and RUTENBERG, N. Pesquisa sobre sade familiar no Nordeste Brasil 1991. [Survey of family health in northeast Brazil.] [POR] Rio de Janeiro. and Columbia, Maryland, Sociedade Civil Bem-Estar Familiar no Brasil. and Macro International, Oct. 1992.247 p.

83.FINGER,W.R. Injectables use increasing rapidly. Network 15(4):20. Jun. 1995.

84. FOREIT, J. (Population Council) [Introducing DMPA in Latin America) Personal communication, Mar. 7,1994

85. FOTHERBY, K. Factors affecting the duration of action at the injectable contraceptive norethisterone enanthate. Contraceptive Delivery Systems 2(3): 249-257. Jul. 1981.

86. FOTHERBY, K., BENAGIANO, G., TOPPOZADA, H.K., ABDEL-RAHMAN, A., NAVAROLI, F., ARCE, B., RAMOS-CORDERO, K., GUAL, C., LANDGREN, B.-M., and JOHANNISSON, E. A preliminary pharmacological trial of the monthy injectable contraceptive Cycloprovera. Contraception 25(3):261-272. Mar. 1982.

87. FOTHERBY, K., SHI, Y.-E., HOWARD, G., ELDER, M.G., and MUGGERIDGE,J. Return of ovulation and fertility in women using noreshisterone oenanthate. Contraception 29(5): 447- 455. May 1984.

88. FRASER, I.S. A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives. Contraception 28(4): 385-397. Oct. 1983.

89. FRASER, I.S. Vaginal bleeding patterns in women using once-a-month injectable contraceptives. Contraception 49(4): 399-420. Apr. 1994.

90. FUTURES GROUP. Integrating Depo-Provera in Nepal's social marketing initiative: What mechanisms are being developed to ensure high quality services? SOMARC III Highlights, Nº. 8. DK. 1993.2 p.

91. GARCEAU, R. (Upjohn) [Depo in India] Personal communication, Feb. 3, 1994.

92. GARDNER, J.M. and MISHELL, D.R., Jr. Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive. Fertility and Sterility 21(4):286-291. Apr. 1970.

93. GARZA-FLORES, I., DE LA CRUZ, D.L., VALLES DE BOURGES, V, SANCHEZ- NUNCIO, R., MARTINEZ, M., FUZIWARA, J.L., and PEREZ- PALACIOS, G. Long-term effects of depot-mdroxyprogesterone acetate on lipoprotein metabolism. Contraception 44(1):61-71. Jul. 1991.

94. GIWA-OSAGIE, O. F, and WORLD HEALTH ORGANIZATION. Metabolic effects of once-a-month combined injectable contraceptives. Contraception 49(5): 421-433. May 1994.

95.GOODSMITH,L. (Population Communication Services) [DMPA in Guinea] Personal communication, Jun. 13,1995.

96. GRABOWSKY, M., HADLER, S., CHEN, B., and BOND, W. Risk of human immunodeficiency virus or Hepatitis-B virus transmission through jet injectors or needles and syringes. [Draft] Aug. 1994. 22 p.

97. GRAY, R. (Johns Hopkins School of Public Health) [injectable services] Personal communication, DK. 2,1993.

98. GRAY, R.H. Depot medroxyprogesterone and risk of breast cancer [Letter] British Medical Journal 299(6707):1099. Oct. 28,1989.

99. GRAY, R.H. Reduced risk of pelvic inflammatory disease with Injectable contraceptives. Lancet 1(8436):1046. May 4,1985.

100. GRAY, R.H. and PARDTHAISONG, T. The authors' response to Hogue. American Journal of Epidemiology 134(8): 816-.817.1991.

101. GRAY, R. and PARDTHAISONG, T. In utero exposure to steroid contraceptives and survival during infancy. American journal of Epidemiology 134(8): 804-811. Oct. 15, 1991.

102. GRAY, R.H., PARDTHAISONG, T., MCDANIEL, E.B., and DOYLE, P. The timing of the first injection of Depo Provera, [Letter to the editor] IPPF Medical Bulletin 9(5): 3-4. Oct. 1975.

103. GRAY, R.H., PARKER, R.A., and DIETHELM, P. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. British journal of Obstetrics and Gynaecology 88(3): 317-32 1. Mar. 1981.

104. GREENSPAN, A.R., HATCHER, R.A., MOORE, M., ROSENBERG, M.J., and DRY, H.W. The association of depo-medroxyprogesterone acetate and breast cancer. Contraception 21(6); 563-569. Jun. 1980.

105. GRIFFIN, M., HEATON, D.A., and MCEWAN, I.A. Long-term use of an injectable contraceptive: Effect of depot-norethisterone oenanthate on carbohydrate metabolism. Contraception 37(1): 53-60. Jan. 1988.

106.GRUBB,G. Critique of Pardthaisong and Gray in utero exposure to steroid contraceptives and outcome of pregnancy. May 29,1992. 4 p. (Unpublished) 107. GULATI, K., MAPA, M.K., GUPTA, A.N., SINGH, P.M., and DEVI, RK. Norethisterone genanthate as an injectable contraceptive in two treatment schedules in interval subjects. Asia-Oceania Journal of Obstetrics and Gynaecology 10(3): 281-286. Sep. 1984.

108. HAIBA, N.A., EL-HABASHY, M.A., SAID, S.A., DARWISH, E.A, ABDELSAYED, W.S., and NAYEL, S.F. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters. Contraception 39(6): 619-632. Jun. 1989.

109. HALL, P.E. (World Health Organization) [injectable contraceptives] Personal communication, jun. 1, 1993 and Apr. 24, 1995.

*110. HALL, P.E. and WORLD HEALTH ORGANIZATION. TASK FORCE ON RESEARCH ON INTRODUCTION AND TRANSFER OF TECHNOLOGIES FOR FERTILITY REGULATION. The introduction of Cyclofem into national family planning programmes: Experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Contraception 49(5): 489-507. May 1994.

111. HARDON,A.P. The needs of women versus the interests of family planning personnel, policy-makers and researchers: Conflicting views on safety will acceptability of contraceptives. Social Science and Medicine 35(6):753-766. 1992.

112. HAREL, Z., BIRO, F.M., and KOLLAR, L.M. Depo-Provera in adolescents: Effects of early wood injection or prim oral contraception. Journal of Adolescent Health 16(5):379-384. May 1995.

113. HART, C., LAMA, U.C. SHYAM, and PROPER, W. (John Snow) [injectables] Personal communication, Apr. 28,1995.

114. HART, C. (John Snow) [Shortening the pipeline for injectables] Personal communication, Jan. 20,1995.

115. HASSAN, E. D., EL-NAHAL, N. and EL-HUSSEIN, M. Acceptability of the once-a-month injectable contraceptives Cyclofem and Mesigyna In Egypt. Contraception 49(5): 469-488. May 1994.

116. HATCHER, R.A., TRUSSELL, J., STEWART, F., STEWART, G.K., KOWAL, D., GUEST, F., CATES, W., Ic, and POLICAR, M.S. Contraceptive technology. 16th rev. ed. New York, Irvington Publishers, 1994. 747 p.

117. HEATON, L. Background briefing book for CRS social marketing project in Nepal: Based on a review of secondary research. Glastonbury, Connecticut, Futures Group, International, Aug. 1993.127 p.

118. HESLING, C. (UNFPA) [Procurement and logistics of injectables] Personal communication, Dec. 29,1993 and Mar. 9,1995.

119. HESS, R. (PCS) [Social drama in Pakistan] Personal communication, Oct. 5, 1993.

120. HOGUE, C.J.R. Invited commentary: The contraceptive technology tight-rope. American Journal of Epidemiology 134(8): 812-815.1991,

121. HOWARD, G., BLAIR, M., DAVIS, H., and TREACY, M. The effect of norethisterone oenanthate on the full blood count. British journal of Family Planning 8(4):125-129. Jan. 1983.

122. HOWARD, G., BLAIR, M., FOTHERBY, K., ELDER, M.G., and BYE, P. Seven years clinical experience of the injectable contraceptive, norethisterone oenanthate. British Journal of Family Planning 11 (1): 9-16. Apr. 1985.

123. HOWARD, G., BLAIR, M., FOTHERBY, K., TRAYNER, I., HAMAWI, A., and ELDER,M.G. Some metabolic effects of long-term use of the injectable contraceptive norethisterone oenanthate. Lancet 1(8269): 423-425. Feb. 20,1982.

124. HOWARD, G., MYATT, L., and ELDER, M.G. The effects of intramuscular norethisterone oenanthate used as a contraceptive on intravenous glucose tolerance and on blood coagulation factors VII and X British journal of Obstetrics and Gynaecology 84(8): 618-621. Aug. 1977.

125. HUBER, D. A case study: DMPA reintroduced in the Philippines. Presented at the Cooperating Agencies Meeting of the US Agency for International Development, Washington, D.C., Feb. 23,1994. 4 p.

126. HUBER, D.G., KHAN, A.R., BROWN, K., MALAKAR, M., and WAIT, G. Oral and injectable contraceptives: Effects on breast milk and child growth in Bangladesh. In: Zatuchni, G.L, Labbolk, M.H., and Sciarra, J.J., eds. Research frontiers in fertility regulation. Hagerstown, Maryland, Harper & go., 1980. (PARFR Series on Fertility Regulation) p. 127-135.

127. HUEZO, C. and MALHOTRA. U. Choice and use-continuation of methods of contraception: A multicentre study. London, International Planned Parent. hood Federation, 1993. p. 97,108.

128. HUQUE, A.A.Z., KOBLINSKY, M.A., and PHILLIPS, J.F. Operational barriers to implementing a domiciliary injectable contraceptive programme in rural Bangladesh. Presented at the Bangladesh Population Association Conference, Dhaka, Aug. 1984.16 p.

129. INDIAN COUNCIL OF MEDICAL RESEARCH. NATIONAL PROGRAMME OF RESEARCH IN HUMAN REPRODUCTION. TASK FORCE ON HORMONAL CONTRACEPTION. Comparative evaluation of contraceptive efficacy of norethisterone oenanthate (200mg) injectable contraceptive given every two or three months. Contraception 30(6):561-574. Dec. 1984.

130. INDIAN COUNCIL OF MEDICAL RESEARCH. TASK FORCE ON HORMONAL CONTRACEPTION. A multicentre Phase III comparative study of two hormonal contraceptive preparations NET-OEN (50 mill plus E2 valerate (5 mg) given every month and NET-OEN (200 mg) given every 2 months as intramuscular injection. A report of a 12-month study. Contraception 42(2):179-190. Aug. 1990.

131. INDONESIA. CENTRAL BUREAU OF STATISTICS (CBS). and NATIONAL FAMILY PLANNING COORDINATING BOARD (NFPCB). and MINISTRY OF HEALTH (MOH). and DEMOGRAPHIC HEALTH SURVEYS (DHS). MACRO INTERNATIONAL. Indonesia Demographic and Health Survey 1994: Prelimi.nary report. [Jakarta, Indonesia]. and Calverton, Maryland, CBS. and MOH. and NFPCB., and DHS, Jan. 1995. 67 p.

132. INDONESIAN SOCIETY OF OBSTETRICS AND GYNECOLOGY (POGI). and JHPIEGO Corporation. and NATIONAL FAMILY PLANNING COORDINATING BOARD (BKKBN). Refresher course handout: DMPA. [Jakarta]. and Baltimore, Apr. 1995. 33 p. (Mimeo)

133. INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH (ICDDR,B). Injectable contraceptives: The use of reusable versus disposable needles and syringes. (Dhaka], Bangladesh, ICDDR,B, DK. 1987. fiMCH-FP Extension Project Briefing Paper Nº. 3) 3 p.

134. INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH (ICDDR,B). The use for one brand of injectables within the Bangladesh family planning program. (Dhaka], Bangladesh, ICDDR,B, Mar. 1991. (MCH-FP Extension Project Briefing Paper Nº. 16) 3 p.

135. INTERNATIONAL INSTITUTE FOR POPULATION SCIENCES (JIPS). National family health survey MCH and family planning): India 1992-93. Intro,ductory report. Bombay, IIPS, Oct. 1994. 91 p.

136. INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IFFP). INTERNATIONAL MEDICAL ADVISORY PANEL. Statement on injectable contraceptioni. IPPF Medical Bulletin 16(6): 3-4. DK. 1982.

*137. INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF). Medical and service delivery guidelines for family planning. London, IPPF, 1992. 169 p.

138. INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF). Statement on injectable contraception. London, IPPF, 1992.6 p. (Mimeo)

*139. ISAACS, W.A. and HAYHOE, F.G.J. Steroid hormones in sickle-cell disease. Nature 215(5106):1139-1142. Sep. 9,1967.

140. JABRE, B., KAIDBEY, M., STOREY, D., JAROUDI, L., MORGAN, W., and WAFAI, M. Madmuun and Murah; A summary of findings from family planning research in Egypt, 1988-1993. [ENG, ARA) Baltimore, Johns Hopkins School of Public Health, Center for Communication Programs, 1994. 32 p.

141. JANERICH, D.T. and HOFF, M.B. Evidence for a crossover in breast cancer risk factors. American Journal of Epidemiology 116(5): 737-742. Nov. 1982.

142. JATO, M. Tanzania: Communication campaign sparks a growing awareness of family planning needs, methods and practice in Dar-es-Salaam, Kisarawe and Mwanga 1994. (Draft] Sep. 1994. 47 p.

143. JIMENEZ, J., OCHOA, M., SOLER, M.P., and PORTALES, P. Long-term follow-up of children preastfed by mothers receiving depo-medroxyprogesterone, acetate. Contraception 30(6): 523-533. Dec., 1984.

144. JOHAL, K. (JSI, JHPIEGO) [injectable training] Personal communication, DK. 27,1994.

145. JOHAL, S. (IPPF) [Procurement of injectables] Personal communication, Feb. 10, 1995.

146. JOHN, H.M. Use of Depo in a community health program in southern India. in: World Neighbors. Second Asian Regional Workshop on Injectable Contraceptives. Oklahoma City, Oklahoma, World Neighbors, 1982. p. 18-21. 147. JOHNS HOPKINS UNIVERSITY. POPULATION COMMUNICATION PROGRAMS (PCS). Pakistan: Report on technical assistance to the Ministry of Population Welfare, Government of Pakistan. Aug. 1990-Jun. 30, 1993. Baltimore, PCS, 1993. (Mimeo)

148. JORDAN, A. FDA requirements for nonclinical testing of contraceptive steroids. Contraception 46(6): 499-509. Dec. 1992.

149. JUNKMANN, K. Uber protrahiert wirksame, Gestagene. Ion the prolonged action of gestagens.][GER] Naunyn-Schmeidebergs Archiv fr Experimentelle Pathologie und Pharmakologie 223: 244-253. 1954.

150. JUNKMANN, K. and WITZEL, H. Chemie and pharmakologie von Steroid-hormon-Estern. (Chemistry and pharmacology of steroidal hormone esterns.][GER] Zeischrift fr Vitamin, Hormon, und Fermentforschung 9: 97-143. 1958.

151. KALTER, H. and WARKANY, J. Congenital malformations: 1. Etiologic factors and their role in prevention. New England Journal of Medicine 308(8): 424-431. Feb. 24, 1983.

152. KARIM, M., AMMAR, R., EL MAHGOUB, S., EL GANZOURY, B., FIKRI, F., and ABDOU, I. injected progestogen and lactation. British Medical Journal 1(5742): 200-203. Jan. 23, 1971.

153. KATJIUANJO, P., TITUS, S., ZAUANA, M., and BOERMA, J.T. Namibia Demographic and Health Survey 1992. Windhoek, Namibia. and Columbia, Maryland, Namibia Ministry of Health and Social Services. and Macro International. Demographic and Health Surveys, May 1993. 221 p.

154. KAUNTIZ A. (University of Florida) [Depo-Provera] Personal communication, Jan. 28,1994 and Jul. 7,1995.

155. KEITH, L. and BERGER, G.S. The relationship between congenital defects and the use of exogenous progestational contraceptive hormones during pregnancy: A 20-year review. International Journal of Gynaecology and Obstetrics 15(2):115-124. Sep.-Oct. 1977.

156. KENYA. NATIONAL COUNCIL FOR POPULATION AND DEVELOPMENT. CENTRAL BUREAU OF STATISTICS (CBS). and MACRO INTERNATIONAL (MI). DEMOGRAPHIC AND HEALTH SURVEYS. Kenya Demographic and Health Survey 1993. Nairobi. and Calverton, Maryland, CBS. and MJ, May 1994. 278 p.

157. KESSERU, E.V, AYDINLIK, S., and ETCHEPAREBORDA, J.J. Multicentred, Phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report. Contraception 50; 329-337. Oct. 1994.

158. KESSERU, E.V. and TOZZINI, R. monthly injectable contraception with norethisterone enanthate plus estradiol valerate. In: Female contraception. Berlin, Springer-Verlag, 1988. p. 221-226.

159. KEW, M.C., SONG, E,, MOHAMMED, A., and HODKINSON, J. Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case/control study in South African black women. Hepatology 11 (2): 298-302. Feb. 1990.

160. KIM, Y.-M., MARANGWANDA, C., DLODLO, B., and KOLS, A. Involving men in family planning: The male motivation and family planning method expansion project, 1993-1994. Baltimore, Johns Hopkins School of Public Health, Center for Communication Program, Jun. 1995. (Forthcoming CCP Working Paper)

161. KINCAID, D.L., COLEMAN, P.L., and RIMON, J.G. 2nd. The national communication campaign of the Philippines 1993-1994: Key research findings. Baltimore, Johns Hopkins Center fix Communication Programs, 1994. 25 p. (Mimeo)

162. KLUGMAN, B. The politics of contraception in South Africa. Womens Studies International Forum 13(3): 261-271. 1990.

163. KNODEL, J. (institute of Population Studies, Chulalongkorn University) [Vietnam survey findings] Personal communication, May 29,1995.

164. KOENIG, M.A., ROB, U., KHAN, M.A., CHAKRABORTY, J., and FAUVEAU, V. Contraceptive use in Matlab, Bangladesh in 1990: Levels, trends, and explanations. Studies in Family Planning 23(6): 352-364.

165. KOETSAWANG, 5. Experience with injectable contraceptives in Thailand. British Journal of Family Planning 12(4, Suppl.): 6-14. ]an. 1987.

166. KOETSAWANG, S. Once-a-month injectable contraceptives: Efficacy and reasons for discontinuation. Contraception 49(4): 387-397. Apr. 1994.

167. KOETSAWANG, S. (Siriraj Family Planning Research Centre) [Thai experience with NET EN and DMPA] Personal communication, Jun. 3, 1993 and Apr 19,1995.

168. KOETSAWANG, S., BOONYAPRAKOB, V, SUVANICHATI, S., and PAIPEEKUL. S. Long-term study of growth and development of children breastled by mothers receiving Depo- Provera (medroxyprogesterone acetate) during lactation. in: Zatuchni, G.L., Goldsmith, A., Shelton, J.D., and Sciarra, J.J., eds. Longf-acting contraceptive delivery "arms. Philadelphia, Harm & Row, 1984. p. 378-387.

169. KOETSAWANG, 5., SRISUPHANDIT, S., SRIVANABOON, S., BHIRALEUS, P., RACHAWAT, D., KIRIWAT, 0., and KOETSAWANG, A. Intramuscular depomedroxyprogesterone acetate for contraception. Journal of the Medical Association of Thailand 57(8): 396,406. Aug. 1974.

170. KONATÉ, D.L., SINARÉ, T, and SEROUSSI, M. Enquête Démographique et de Santé Burkina Faso 1993. (Demographic and Health Survey Burkina Faso 1993.] [FRE] Ouagadougou, Burkina Faso, Burkina Faso National Institute of Statistics and Demography. and Macro International, Jun. 1994. 296 p.

171. KOUAKOU KOUASSI, L., KOUAME, K., and HUNTINGTON , D . Analyse situationnelle do programme d'extension des services de planification familiale en Côte d'ivoire [Situation analysis of the program to extend family planning services in Côte d'Ivoire. [FRE] [Abidjan], Côte d'Ivoire, Association Ivorienne Pour Le Bien-être Familial. and Population Council, Sep. 1992.62 p.

172. KRAYACICH DE ODDONE, N., SHEDLIN, M.G., WELSH, M., POTTS, M., and FELDBLUM, P. Paraguayan pharmacies and the sale of pseudo-abortifacilents. Joumal of Biosocial Science 23(2):201-209. Apr. 1991.

173. KRISTENSEN, D.D. (Program for Appropriate Technology in Health) [Delivery systems and shelf-life] Personal communication, Jan. 18, 1994 and Jun. 28, 1995.

174. KUSEKA, I. and SILBERMAN, T. Male motivation impact evaluation survey. Harare, Zimbabwe, Zimbabwe National Family Planning Council, Jun. 1990. 152 p.

175. LABBOK, M.H. and LAUKARAN, VH. Postpartum family planning choices for the lactating woman: The use of Norplant and Depo-Provera.[Abstract 3231] In: American Public Health Association (APHA). Abstracts: American Public Health Association 122nd Annual Meeting and Exhibition, Oct. 30-Nov. 31 1994, Washington, D C. Washington D.C., APHA, 1994. p. 368.

176. LAING, J.E. Continuation and effectiveness of contraceptive practice- A cross-sectional approach. Studies in Family Planning 16(3):138-1 53. May-Jun. 1985.

177. LAM& U.C.S. (John Snow) [Logistics for injectables] Personal communication, Jan. 14,1994.

178. LAMBE, M., HSIEH, C.-C., TRICHOPOULOS, D., EKBOM, A., PAVIA, M., and ADAMI, H.-O. Transient increase in the risk of breast cancer after giving birth. New England journal of Medicine 331(1):5-9. Jul. 7,1994.

179. LANDE, R-E. and BLACKBURN, R. Pharmacists and family planning. Population Reports, Series J, Nº. 37. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Nov, 1989. 32 p.

180. LEE, N.C., ROSERO-BIXBY, L., OBERLE, M.W., GRIMALDO, C., WHATLEY, A-S., and ROVIRA. EZ A case-control study of breast cancer and hormornal contraception In Costa Rica. journal of the National Cancer Institute 79(6):1247-1254. Dec. 1987.

181. LEN, F.R., HURTADO, R., and MONGE, R. Provider knowledge concerning Depo- Provera and other contraceptives before and after training: A study in rural Pew. DK. 31,1992. 27 p. (Unpublished)

182. LERMAN, C., MOLYNEAUX, J.W., MOELJODIHARDIO, S., and PANDJAITAN, S. The correlation between family planning program inputs and contraceptive use in Indonesia. Studies in Family Planning 20(1): 26-37. Jan.-Feb. 1989.

183. LIANG, A.P., LEVENSON, A.C., LAYDE, P.M., SHELTON, J.D., HATCHER, R.A., POTTS, M., and MICHELSON, M.J. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. Journal of the American Medical Association 249(21); 2909-2912. Jun. 3,1983.


Population Reports is published by the Population Information Program, Center for Communication Programs, The Johns Hopkins School of Public Health, 111 Market Place, Suite 310, Baltimore, Maryland 21202-4012, USA

Palavras chave: acetate, injectable, medroxyprogesterone acetate, medroxyprogesterone, contraception, and , effects, injectable contraceptives, family, depot medroxyprogesterone acetate, dk, family planning, depot medroxyprogesterone, m, p , 3, bangladesh, depot, p, rese

Divulgação



Publicidade

conteúdos relacionados

Artigo / Publicado em 18 de janeiro de 2013

Riscos Trombóticos Associados aos Contraceptivos

Artigo / Publicado em 19 de março de 2002

Terapia de Reposição Hormonal: estado atual 2002 e seu futuro

Artigo / Publicado em 22 de agosto de 2000

Bibliografia - 1ª Parte

Artigo / Publicado em 17 de fevereiro de 2003

Referências Bibliográficas - 2ª Parte

Artigo / Publicado em 4 de janeiro de 2010

Contornando problemas associados aos Anticoncepcionais Orais: relato de caso

Artigo / Publicado em 22 de agosto de 2000

Bibliografia - 1ª Parte

Notícia / Publicada em 22 de junho de 2011

Cigarros mentolados deveriam ser retirados do mercado

Notícia / Publicada em 4 de dezembro de 2008

Métodos de medicina complementar e alternativa para redução da PA

Notícia / Publicada em 19 de setembro de 2008

Uso de esteróides orais no tratamento inicial da lombalgia aguda: é justificável?

Notícia / Publicada em 4 de julho de 2000

Os Preservativos Femininos Podem Aumentar a Constância do Uso dos Métodos de Barreira



© 2000 - 2019 Bibliomed, Inc. Todos os Direitos Reservados contato imprensa